Sofosbuvir + Velpatasvir Tablet IP 400mg/100mg (Mylan)

Sofosbuvir & Velpatasvir (brand: MyHep All by Mylan) is a potent combination antiviral treatment indicated for chronic hepatitis C virus (HCV) infection, effective against all major HCV genotypes (1 through 6), whether or not the patient has cirrhosis. Hepatitis C Online +3 Medindia +3 hcp.epclusa.com +3 Mechanism of action: Sofosbuvir is an NS5B polymerase inhibitor that halts viral RNA replication; Velpatasvir is an NS5A inhibitor disrupting viral replication complexes. Together they block different steps in the virus lifecycle. Drugs.com +1 Dosage: For adults and children ≥ 3 years old, one tablet (400/100 mg) once daily for 12 weeks. The tablet may be taken with or without food. Use the full course even if you feel better. Mayo Clinic +2 Drugs.com +2 Special populations: Patients with compensated or decompensated cirrhosis may need longer or additional therapy (for example, adding ribavirin) as guided by a doctor. Use in children < 3 years or < weight thresholds may involve different formulations (pellets). Mayo Clinic +1 Key precautions / interactions: Don’t use with strong inducers of P-gp or CYP450 enzymes (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) → can reduce drug concentration and reduce efficacy. efda.gov.et +1 Monitor for hepatitis B co-infection, which may flare when treating HCV. hcp.epclusa.com +1 Possible side effects: fatigue, headache, nausea, insomnia, rash, etc. Most are mild to moderate.